Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 606, Issue 1-2, 2006, Pages 52-60

  Oka, Hiroaki ^a   Ikeda, Kazumasa ^a   Yoshimura, Hiromi ^a   Ohuchida, Akinobu ^a   Honma, Masamitsu ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

5 fluorouracil; In vitro micronucleus assay; p53; Tk assay

Indexed keywords

CLASTOGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; THYMIDINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETOXIFICATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL LINE; MICRONUCLEUS; MOUSE; MUTAGENICITY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL DEATH; DRUG EFFECT; DRUG SCREENING; METABOLISM; MICRONUCLEUS TEST; TIME;

ANIMALS; CELL COUNT; CELL CYCLE; CELL DEATH; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; MICE; MICRONUCLEUS TESTS; MODELS, BIOLOGICAL; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746460874     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2006.02.001     Document Type: Article

References (43)

1. +/- mouse lymphoma forward mutation assay using 42 chemicals. Mutat. Res. 125 (1984) 291-306
2. Clay P., and Cross M.F. Microwell mutation assays: evaluation of ethyl methanesulfonate, benzo[a]pyrene and benzidine using the tk locus in L5178Y mouse lymphoma cells. Mutagenesis 5 Suppl. (1990) 45-54
3. Honma M., Hayashi M., and Sofuni T. Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells. Mutat. Res. 374 (1997) 89-98
4. Honma M., Zhang L.S., Hayashi M., Takeshita K., Nakagawa Y., Tanaka N., and Sofuni T. Illegitimate recombination leading to allelic loss and unbalanced translocation in p53-mutated human lymphoblastoid cells. Mol. Cell. Biol. 17 (1997) 4774-4781
5. Honma M., Hayashi M., Shimada H., Tanaka N., Wakuri S., Awogi T., Yamamoto K.I., Kodani N., Nishi Y., Nakadate M., and Sofuni T. Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 14 (1999) 5-22
6. Clive D., and Spector J.F.S. Laboratory procedure assessing specific locus mutation at the TK locus in cultured L5178Y mouse lymphoma cells. Mutat. Res. 31 (1975) 17-29
7. Leong-Morgenthaler P.M., Velt C.O.H., Jaccaud E., and Turesky R.J. Mutagenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in human lymphoblastoid cells. Carcinogenesis 19 (1998) 1749-1754
8. Chuang Y.Y., Chen Q., Brown J.P., Sedivy J.M., and Liber H.L. Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res. 59 (1999) 3073-3076
9. Branda R.F., O'Neill J.P., Brooks E.M., Trombley L.M., and Nicklas J.A. The effect of folate deficiency on the cytotoxic and mutagenic responses to ethyl methanesulfonate in human lymphoblastoid cell lines that differ in p53 status. Mutat. Res. 473 (2001) 51-71
10. Bassi L., Carloni M., Fonti E., de la Pena N.P., Meschini R., and Palitti F. Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Mutat. Res. 499 (2002) 163-176
11. Amundson S.A., Xia F., Wolfson K., and Liber H.L. Different cytotoxic and mutagenic responses induced by X-rays in two human lymphoblastoid cell lines derived from a single donor. Mutat. Res. 286 (1993) 233-241
12. Xia F., Wang X., Wang Y.H., Tsang N.M., Yandell D.W., Kelsey K.T., and Liber H.L. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55 (1995) 12-15
13. Morris S.M. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 511 (2002) 45-62
14. Schwartz J.L., Jordan R., Sedita B.A., Swenningson M.J., Banath J.P., and Olive P.L. Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis. Mutagenesis 10 (1995) 227-233
15. Arango D., Corner G.A., Wadler S., Catalano P.J., and Augenlicht L.H. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61 (2001) 4910-4915
16. Grem J.L., Danenberg K.D., Behan K., Parr A., Young L., Danenberg P.V., Nguyen D., Drake J., Monks A., and Allegra C.J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 7 (2001) 999-1009
17. Longley D.B., Boyer J., Allen W.L., Latif T., Ferguson P.R., Maxwell P.J., McDermott U., Lynch M., Harkin D.P., and Johnston P.G. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 62 (2002) 2644-2649
18. Greenwood S.K., Armstrong M.J., Hill R.B., Bradt C.I., Johnson T.E., Hilliard C.A., and Galloway S.M. Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53. Mutat. Res. 401 (1998) 39-53
19. Allio T., Donner E.M., and Preston R.J. A comparison of the roles of p53 mutation and AraC inhibition in the enhancement of bleomycin-induced chromatid aberrations in mouse and human cells. Mutat. Res. 447 (2000) 227-237
20. Allio T., and Preston R.J. Increased sensitivity to chromatid aberration induction by bleomycin and neocarzinostatin results from alterations in a DNA damage response pathway. Mutat. Res. 453 (2000) 5-15
21. Zhang L.S., Honma M., Hayashi M., Suzuki T., Matsuoka A., and Sofuni T. A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test. Mutat. Res. 347 (1995) 105-115
22. +/- cell line is heterozygous for a codon 170 mutation in the p53 tumor suppressor gene. Mutat. Res. 373 (1997) 157-165
23. Piper A.A., and Fox R.M. Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil. Cancer Res. 42 (1982) 3753-3760
24. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16 (1989) 215-237
25. Thomas D.M., and Zalcberg J.R. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 25 (1998) 887-895
26. 5-fluorouracil. IARC Monogr. Eval. Carcinogen. Risk Chem. Hum. 26 (1981) 217-235
27. Griffiths L., and Stratford I.J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br. J. Cancer 76 (1997) 689-693
28. Yajima N., Kondo K., and Morita K. Reverse mutation tests in Salmonella typhimurium and chromosomal aberration tests in mammalian cells in culture on fluorinated pyrimidine derivatives. Mutat. Res. 88 (1981) 241-254
29. Ohuchida A., Furukawa A., Yoshida J., Watanabe M., Aruga F., Miwa Y., Shinkawa K., and Kinae N. Micronucleus assays on 5-fluorouracil and 6-mercaptopurine with mouse peripheral blood reticulocytes. Mutat. Res. 278 (1992) 139-143
30. Sofuni T., Honma M., Hayashi M., Shimada H., Tanaka N., Wakuri S., Awogi T., Yamamoto K.I., Nishi Y., and Nakadate M. Detection of in vitro clastogens and spindle poisons by the mouse lymphoma assay using the microwell method: interim report of an international collaborative study. Mutagenesis 11 (1996) 349-355
31. 5-fluorouracil. IARC Monogr. Eval. Carcinogen. Risk Chem. Hum. Suppl. 6 (1987) 316-318
32. Matsushima T., Hayashi M., Matsuoka A., Ishidate M., Miura K.F., Shimizu H., Suzuki Y., Morimoto K., Ogura H., Mure K., Koshi K., and Sofuni T. Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU). Mutagenesis 14 (1999) 569-580
33. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493-501
34. Carbonari M., Cibati M., and Fiorilli M. Measurement of apoptotic cells in peripheral blood. Cytometry 22 (1995) 161-167
35. Spears C.P., Shahinian A.H., Moran R.G., Heidelberger C., and Corbett T.H. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 42 (1982) 450-456
36. Takechi T., Uchida J., and Fukushima F.A.M. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int. J. Oncol. 11 (1997) 1041-1044
37. Naguib F.N., el Kouni M.H., and Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45 (1985) 5405-5412
38. Peters G.J., Laurensse E., Leyva A., Lankelma J., and Pinedo H.M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46 (1986) 20-28
39. Maehara Y., Nakamura H., Nakane Y., Kawai K., Okamoto M., Nagayama S., Shirasaka T., and Fujii S. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann 73 (1982) 289-298
40. Ingraham H.A., Tseng B.Y., and Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol. Pharmacol. 21 (1982) 211-216
41. Curtin N.J., Harris A.L., and Aherne G.W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 51 (1991) 2346-2352
42. Ladner R.D. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr. Protein Pept. Sci. 2 (2001) 361-370
43. Fukushima M., Murakami Y., Suzuki N., and Aiba K. The analysis of the innate pathways of 5-fluorouracil phosphorylation in human gastrointestinal cancer cell lines in vitro and in vivo. Oncol. Rep. 4 (1997) 1189-1194